Daniel S. Levine

Daniel S. Levine is editor of Rare Daily. You can contact him by sending email to editor@globalgenes.org

FDA Eliminates Orphan Drug Designation Backlog, But Sets Stage for Controversial Changes
Rare Daily Staff U.S. Food and Drug Administration Commissioner Scott Gottlieb said the agency has eliminated a backlog of about 200… Continue Reading
Alexion to Slash 20 Percent of Staff, Relocate HQ as Part of Restructuring
Rare Daily Staff Rare disease drugmaker Alexion Pharmaceuticals said it would eliminate 20 percent of its workforce and move its… Continue Reading
Shire Reports HAE Treatment Superior to Placebo in Late-Stage Study
Rare Daily Staff Shire released positive results from a late-stage study of its experimental C1 esterase inhibitor therapy for Hereditary… Continue Reading
Alnylam Halts Dosing in Trials of RNAi Therapy for Hemophilia After Patient Death
Rare Daily Staff Alnylam Pharmaceuticals said it has halted dosing in ongoing trials following the death of a 78-year-old man with… Continue Reading
Bioverativ and Bicycle Enter Collaboration Targeting Rare Blood Disorders
Rare Daily Staff Biogen spin-out Bioverativ said it entered into a collaboration with Bicycle Therapeutics focused on the discovery,… Continue Reading
NIH awards nearly $100 million for Autism Centers of Excellence
Rare Daily Staff The National Institutes of Health said it made nine awards of research grants totaling nearly $100 million over the next… Continue Reading
RARECast: A Veteran Venture Capitalist Discusses Investing in Rare Disease Drug Development
  Art Pappas, a former pharmaceutical executive turned venture capitalist, has spent more than 30 years working for and investing in drug… Continue Reading